Although no clinical data is currently available for its use in thyroid cancer, there is an ongoing phase 2 trial examining encorafenib combined with binimetinib, with or without immunotherapy (nivolumab), in patients with metastatic BRAF V600E mutant RR-DTC (NCT04061980). The gene discussed is BRAF; the disease is thyroid gland carcinoma.